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The aim of the study is to compare counting of colony forming units (CFU), the time to positivity (TTP)
assay and the molecular bacterial load (MBL) assay, and explore whether the last assays can detect a
subpopulation which is unable to grown on solid media. CFU counting, TTP and the MBL assay were used
to determine the mycobacterial load in matched lung samples of a murine tuberculosis model. Mice were
treated for 24 weeks with 4 treatment arms: isoniazid (H) - rifampicin (R) - pyrazinamide (Z), HRZ-
Streptomycin (S), HRZ e ethambutol (E) or ZES.
Inverse relationships were observed when comparing TPP with CFU or MBL. Positive associations were
observed when comparing CFU with MBL. Description of the net elimination of bacteria was performed
for CFU vs. time, MBL vs. time and 1/TTP vs. time and ﬁtted by nonlinear regression. CFU vs. time and 1/
TTP vs. time showed bi-phasic declines with the exception of HRZE. A similar rank order, based on the
alpha slope, was found comparing CFU vs. time and TTP vs. time, respectively HRZE, HRZ, HRZS and ZES.
In contrast, MBL vs. time showed a mono-phasic decline with a ﬂat gradient of elimination and a
different rank order respectively, ZES, HRZ, HRZE and HRZS. The correlations found between methods
reﬂects the ability of each to discern the general mycobacterial load. Based on the description of net
elimination, we conclude that the MBL assay can detect a subpopulation of Mycobacterium tuberculosis
which is not detected by the CFU or TTP assays.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tuberculosis (TB) is a bacterial infection that affects more than
ten million people globally every year, with 1.8 million deaths
recorded in 2015 and is ranked as a leading cause of death from
infectious diseases worldwide [1].
Mycobacterial populations in TB patients are heterogeneous;
several subpopulations of bacteria have been identiﬁed in the
lungs, in different microenvironments [2]. Environmental stress
and antibiotic pressure can drive Mycobacterium tuberculosis into a
non-replicating state [3,4]. As a consequence, extensive and long-Knegt).
Ltd. This is an open access articleterm treatment is required to eradicate all these subpopulations
ofMycobacterium tuberculosis [5]. In order to shorten the treatment
duration, new drugs and novel combinations are essential and
provide the best opportunity to eliminate all mycobacterial
subpopulations.
For the development of new drugs and regimens, it is important
at an early stage to determine a drug's and regimen's potency to
prevent relapse, which will determine the required treatment
duration with this regimen [6].
Monitoring treatment response provides information that can
be used to make inferences regarding treatment success. Current
methods to monitor treatment response such as sputum smear or
sputum serial colony counting have their drawbacks including loss
of sensitivity, being laboratory intensive [7], or being sensitive to
contamination [8]. As a result, these methods do not predictunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Standard curve of CFU and CT values obtained from a serially diluted Myco-
bacterium tuberculosis stock spiked in naïve lung homogenate.
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precision in predicting the important long-term clinical outcome of
a regimen [9]. Furthermore, it is rather unlikely that all different
subpopulations of Mycobacterium tuberculosis are detected using
these methods [10].
In vitro experiments and animal models often use counting of
colony forming units (CFU) as a parameter to determine the total
bacterial load. It has been shown by Hu et al. that CFU counts are
not always representative for the total population present in an
in vitro system, as well as in the lungs of TB infected mice [11].
Besides the CFU counts found, there was also a population of
Mycobacterium tuberculosis present that could only be detected
when they were resuscitated using resuscitation promoting factors
(RPFs), indicating that basic CFU counting is maybe not the most
optimal parameter to determine the total bacterial load. Therefore
new techniques, which are less dependent on culture viability, are
necessary to provide this information.
In the present study, we used matched lung samples of our
murine TB model to compare CFU counting, liquid culture/time to
positivity (TTP) and the molecular bacterial load (MBL) assay [12].
This MBL assay detects Mycobacterium tuberculosis 16S ribosomal
RNA with a robust internal control (IC) which normalizes for RNA
loss during extraction and the presence of sample inhibitors. By
measuring 16S ribosomal RNA the MBL assay is therefore not
depending on actively growing mycobacteria.
The aim of the study is to compare CFU counting, TTP and the
MBL assay, and explore whether the last assays can detect a
mycobacterial subpopulation which is unable to grown on solid
media.
2. Materials and methods
2.1. Mouse TB model
Speciﬁed pathogen-free female BALB/c mice were obtained
from Charles River (Les Oncins, France). At the day of infection,
animals were 13e15 weeks old and weighed 20e25 g.
Four groups of mice were infected with Mycobacterium tuber-
culosis as described previously [13]. In short, mice under anesthesia
were infected by intra-tracheal instillation of a suspension (40 mL)
containing 1.3  105 CFU (0.7e1.7  105) of the Beijing VN 2002-
1585 genotype strain [14], followed by proper inhalation to ensure
the formation of a bilateral TB infection.
2.2. Antibiotic therapy
Four treatment arms, each with a total length of 6 months (24
weeks) were designed, as part of the research conductedwithin the
PreDiCT-TB consortium: HRZ (2HRZ/4HR), ZES (2ZES/4E), HRZE
(2HRZE/4HR) and HRZS (2HRZS/4HR). All treatment arms started 2
weeks after infection.
Human equivalent doses of antibiotics were used: isoniazid (H)
25 mg/kg, rifampicin (R) 10 mg/kg, pyrazinamide (Z) 150 mg/kg,
streptomycin (S) 200 mg/kg and ethambutol (E) 100 mg/kg [15]. All
drugs were dissolved in water and given orally (0.2 mL) as a bolus,
5x/week, except for S, which was administered subcutaneously.
2.3. Determination of the mycobacterial load in infected lungs
To determine the mycobacterial load in infected lungs, mice
were sacriﬁced by CO2 exposure at the start of therapy and after 1,
2, 4, 8, 12 and 24 weeks of therapy (n ¼ 3). To prevent carry-over of
TB-drugs, therapy was stopped 72 h before sacriﬁcing the mice.
The lungs were removed aseptically and homogenized within
5 min in M-tubes with the gentleMACS Octo Dissociator using theRNA program (Miltenyi Biotec BV, Leiden, the Netherlands) in 2 mL
Phosphate Buffered Saline (PBS).
2.4. Colony forming units counts
From each tissue homogenate 10-fold serial dilutions were
performed and samples of 200 mL were cultured on drug-free 7H10
Middlebrook agar containing activated charcoal (0.4%), and incu-
bated for 28 days at 37 C with 5% CO2 to perform colony counting.
Activated charcoal was added to the agar to inhibit the antibiotic
residue from the tissue samples and prevent carry-over [16]. Lower
limit of quantiﬁcation is 10 CFU per lung.
2.5. Time to positivity
From each tissue homogenate 200 mL was added to a myco-
bacterial growth indicator tube (BBL MGIT; Becton, Dickinson and
Company, MD, USA) in combinationwith 800 mL OADC enrichment.
Tubes were incubated in the Bactec MGIT 960 (Becton, Dickinson
and Company, MD, USA) and TTP was automatically recorded.
2.6. MBL assay
From each tissue homogenate 300 mL was directly preserved in
guanidine thiocyanate (GTC) containing 1% ß-mercaptoethanol and
stored at80 C. MBL assay was performed as previously described
by Honeyborne et al. [12]. In short, following thawing, 50 ng of the
internal control (IC), a 1957-bp RNA molecule that contain parts of
the sol gene from potato tuber (Solanum tuberosum) [12], was
spiked into each tissue sample. The IC normalizes for RNA loss
during extraction and the presence of sample inhibitors. To assign
cycle threshold values to bacterial loads, a standard curve was
prepared. Naïve lung homogenate in GTC was spiked with serial
diluted concentrations of a Mycobacterium tuberculosis stock
ranging from 1.3  107 down to 1 CFU/mL, including the IC (Fig. 1).
Lung homogenate in GTC plus IC was centrifuged (14,000 x
g;20 min) at room temperature, supernatant was discarded and
1 mL of RNApro (FastRNA pro Blue kit; MP Biomedicals) was added
to the pellet. RNA extraction was performed according to the
manufacturer's instructions. DNase I (Turbo DNA-fee kit; Ambion)
was used to remove contaminating DNA.
Expression of 16S-ROX and IC-JOE was measured using multi-
plex reverse transcriptase-quantitative PCR (RT-qPCR). RT-qPCR
G.J. de Knegt et al. / Tuberculosis 105 (2017) 113e118 115was performed on a 7500 Fast Real-Time PCR System (Applied
Biosystems, Bleiswijk, the Netherlands) using a one-step qRT-PCR
MasterMix for probe Assay Low ROX (Eurogentec, Maastricht, the
Netherlands). Primers and dual-labelled probes were also pur-
chased from Eurogentec.
2.7. Data analysis
Data 0e24 weeks of treatment (2e26 weeks following infec-
tion) were used to investigate elimination of bacteria under the
four therapeutic conditions (HRZ, ZES, HRZE, HRZS). Contaminated
CFU (n ¼ 2) and TTP (n ¼ 11) samples were excluded. Correlations
between measurements obtained by CFU, TTP and MBL assay over
time collectively were evaluated by Spearman's Rank (p < 0.017
was considered statistically signiﬁcant at the 5% level incorporating
a Bonferroni correction for 3 pairwise comparisons for each treat-
ment). Given that data from 3 distinct mice were available at eachFig. 2. Mouse lung CFU, MBL and TTP over 24 weeks post-treatment (26 weeks post-Mycob
mean value (n ¼ 3 mice per time point) ± SD with CFU and MBL on the left y-axis and 1/Ttime point, naïve pooling was undertaken for analysis [17]. Math-
ematical models to describe the proﬁles of elimination of bacteria
under treatment were ﬁtted by nonlinear regression to the
observed proﬁles of bacterial load vs. time as measured by CFU, 1/
TTP, and MBL (TTP in broad terms being inversely proportional to
the number of bacteria in the system). Parameter estimates for this
modelling analysis were determined using the nonlinear least
squares optimization function “lsqnonlin” as part of the “pracma”
package in R (www.r-project.org). Standard errors were calculated
using previously described methods by Landaw et al. with the Ja-
cobian of model parameter sensitivities estimated using a numer-
ical central difference method [18]. Exponential growth and death
of bacteria cannot be differentiated with this data (the growth and
death processes may occur simultaneously across the bacterial
population as a whole) therefore exponential rate constants
describing the “net” rate of bacterial growth or death were esti-
mated from the quantitative timecourse proﬁles of bacterial load asacterium tuberculosis infection) with HRZ, ZES, HRZE and HRZS. Data are presented as
TP on the right. The solid and dashed lines represent the modelled ﬁt to the data.
G.J. de Knegt et al. / Tuberculosis 105 (2017) 113e118116determined by the 3 assays. These net rate constants take a nega-
tive value corresponding to net elimination, and a positive one to
describe net growth.
3. Results
The data of lung CFU, MBL and TTP (TTP data is converted to 1/
TTP) over 24 weeks of treatment are illustrated (Fig. 2) and statis-
tical relationships between assays are summarized (Table 1).
Overall, inverse correlations were observed between TTP with CFU
and MBL and positive associations between CFU and MBL with
statistical signiﬁcance for all regimens with the exception of TTP vs.
MBL for ZES and HRZE and CFU vs.MBL for HRZS (Table 1). For HRZ,
HRZE and HRZS, MBL consistently reported lower than CFU be-
tween 2 and 8 weeks post-infection and higher than CFU to 14
weeks and 26 weeks post-infection (Fig. 2).
3.1. Modelling of CFU vs. time
For CFU proﬁles over time (t) from the lung while under therapy
the best description was given by a bi-exponential decline of the
form CFU(t) ¼ A*10^ (-a*t)þB*10 (^-b*t) with the exception of HRZE
for which a mono-phasic decline was supported [CFU(t) ¼ A*10 (^-
a*t)] (Fig. 2). The ﬁrst order exponential rate constants alpha (a)
and beta (b) (in broad terms the “slopes” of the phases of the proﬁle
vs. timewhen plotted on a semi-logarithmic scale) are summarized
(Table 2). Based on the b exponential rate constant, governing the
2nd phase of a multiexponential proﬁle (if 2 exponential phases are
present, and governing the only phase if the proﬁle is mono-phasic)
a rank order HRZE > HRZ > HRZS > ZES was shown, i.e. HRZE
produced the steepest gradient on a logarithmic scale corre-
sponding to a more rapid rate of elimination of bacteria, in contrast
to ZES which actually showed signs of regrowth of bacteria during
the second phase of its proﬁle, though at a slow rate close to stasis
over the 12e24 week period of the study (b of 0.414 vs. þ0.049;
Table 2). The b exponential rate constant is potentially a more
interesting parameter of comparison as it is likely to reﬂect more
the activity of treatment against a slower dying, less drug suscep-
tible mycobacterial subpopulation similarly though, based on a
slope, rate of eliminations were in the order of HRZ > HRZS > ZES
(Table 1) with HRZE for unknown reasons showing only a mono-
phasic decline in this experiment.Table 1
Summary of spearman rank correlation coefﬁcients evaluating the relationships
between assays for measurement of Mycobacterium tuberculosis in mouse lung
following 24weeks treatmentwith HRZ, HRZE, HRZS, ZES (analyses fromweek 2e26
post- Mycobacterium tuberculosis infection). P values highlighted in bold type
represent statistically signiﬁcant correlations with Bonferroni correction of 3 per
drug combination for multiple comparisons (p < 0.017).
Treatment Comparison Rhoa (95% CI) P value
HRZ TTP vs. CFU 0.993 (0.998 to 0.978) <0.0001
CFU vs. MBL 0.846 (0.529e0.956) 0.0008
TTP vs. MBL 0.874 (0.964 to 0.602) 0.0003
HRZE TTP vs. CFU 0.766 (0.911 to 0.452) 0.0005
CFU vs. MBL 0.797 (0.412e0.941) 0.0027
TTP vs. MBL 0.382 (0.799 to 0.283) 0.248
HRZS TTP vs. CFU 0.965 (0.989 to 0.890) <0.0001
CFU vs. MBL 0.507 (0.0069 to 0.809) 0.054
TTP vs. MBL 0.753 (0.922 to 0.345) 0.0044
ZES TTP vs. CFU 0.982 (0.994 to 0.952) <0.0001
CFU vs. MBL 0.492 (0.0888e0.757) 0.010
TTP vs. MBL 0.457 (0.762 to 0.0120) 0.028
CFU: Colony Forming Units; MBL: Molecular Bacterial Load; TTP: Time To Positivity;
H: isoniazid; R: rifampicin; Z: pyrazinamide; S: streptomycin; E: ethambutol; CI:
conﬁdence interval.
a Spearman's rank correlation co-efﬁcient.3.2. Modelling of MBL vs. time
Proﬁles of MBL over time during therapy were described by
mono-phasic declines (Fig. 2). The gradients of the elimination
slopes on the logarithmic scale for each combination therapy were
relatively ﬂat and similar numerically suggesting slow bacterial
elimination for all therapies (Table 2).
3.3. Modelling of TTP vs. time
Given the inverse relationships observed between TTP with CFU
and MBL a bi-exponential elimination model was ﬁtted to 1/TTP vs.
time data in order to determine a comparable elimination rate for
TTP (Fig. 2) (1/TTP being a more directly comparable measure of
bacterial load). Based on the b rate constant, rate of bacterial
decline was of an identical order to that observed for CFU
(HRZE > HRZ > HRZS > ZES) with ZES also showing potential
regrowth (i.e. a positive b rate constant) in the 12e24 week period
as it did in its CFU proﬁle.
4. Discussion
Identiﬁcation of subpopulations ofMycobacterium tuberculosis is
important for drug development, reﬁnement of existing or novel
drug combinations to ultimately achieve therapeutic success in a
clinical setting. Animal models can be particularly useful to eval-
uate potential methods of quantifying different populations of
Mycobacterium tuberculosis [11,19]. One of the beneﬁts of an animal
model is the ability to study the total population of Mycobacterium
tuberculosis in the lung, including the more hidden bacteria in
granuloma like formations, whereas in sputum from TB patient
only the secreted bacteria can be studied [20]. However, animal
studies from the past using CFU counts as a parameter are maybe
not predictive enough because it has been shown by Hu et al. that
CFU counts are not representative for the total population present
in an in vitro systems as well as in the lungs of TB infected mice,
using RPFs to resuscitate a persistent and non-growing population
[11].
We have presented for the ﬁrst time the comparison of CFU, MBL
and TTP methods using matched lung samples from a mouse TB
model and explored the use of mathematical modelling to further
summarize and scrutinize the data, describing the elimination of
Mycobacterium tuberculosis over time for each method under
different therapeutic conditions.
The ability to detect different Mycobacterium tuberculosis pop-
ulations in our mouse TB model using the three methods can be
explained by the principles of the techniques. In contrast to DNA
based assays like the GeneXpert® MTB/RIF assay, the MBL assay
detects the presence and amount of 16S rRNA and is therefore less
hampered by the presence of genomic material of already dead
cells [21]. The 16S rRNA is much more unstable compared to DNA
and degrades much faster [22]. It has been shown that RNA, in
particular mRNA, correlated with solid culture but more closely
with growth in liquid culture [23]. However, for culture on solid
media or in liquid media actual growth is still required, thereby
presenting only the ﬁttest mycobacteria which were capable of
growing. In contrast, for the MBL assay a particular population of
Mycobacterium tuberculosis should be alive, and have metabolic
activity, but actual growth is not required.
Statistically signiﬁcant correlations between assays were
evident for the majority of regimens tested. Lack of association
between TTP vs. MBL for ZES and HRZE and CFU vs. MBL for HRZS
was possibly due to small sample size in these groups. Unsurpris-
ingly, TTP was inversely related to CFU andMBL as a shorter time to
positivity would be expected with high bacterial load measured
Table 2
Parameter estimates and associated percentage relative standard errors (%RSE) for a
and b exponential rate constants describing net bacterial growth/elimination for
each treatment regimen betweenweeks 2e24 of infection. Data analysed by ﬁtting a
bi or mono-exponential model as appropriate.
Treatment a (wk1) %RSE b (wk1) %RSE
CFU vs time
HRZEa e e ¡0.414 9.4
HRZ 1.127 30.4 ¡0.346 7.6
HRZS 0.971 11.2 ¡0.270 19.0
ZES 0.664 9.8 þ0.049 25.6
MBL vs time
ZESa e e ¡0.136 11.4
HRZa e e ¡0.132 4.5
HRZEa e e ¡0.130 10.0
HRZSa e e ¡0.116 10.9
(1/TTP) vs time
HRZE 0.605 19.7 ¡0.038 10.4
HRZ 0.718 14.2 ¡0.032 9.2
HRZS 0.526 12.6 ¡0.030 17.8
ZES 0.276 7.6 þ0.008 18.6
CFU: Colony Forming Units; MBL: Molecular Bacterial Load; TTP: Time To Positivity;
H: isoniazid; R: rifampicin; Z: pyrazinamide; S: streptomycin; E: ethambutol; %RSE:
percentage Relative Standard Error of parameter estimate.
In bold the no. on which the ranking is based on.
a Mono-exponential ﬁtting.
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mycobacterial count CFU was zero, the MGIT will not measure
ﬂuorescence as a result of oxygen consumption and time to posi-
tivity would be inﬁnite, because there are no growingmycobacteria
present.
Mathematical modelling allowed estimation of the elimination
rate of bacteria under each of the four drug combinations. The rates
of elimination of bacteria for HRZ, ZES, HRZE and HRZS asmeasured
by CFU and TTPwere of a similar rank order andwere both typically
bi-exponential in this study. This suggests that CFU and TTP are
measuring similar bacterial populations that show net elimination
under chemotherapy. A study conducted by Diacon et al. showed
that CFU can be substituted with TTP in early bactericidal activity
(EBA) studies [7], but on the other hand, a sample taken at the end
of treatment can take longer to signal positive in MGIT compared to
a sample taken early with a similar CFU count as shown by Bowness
and colleagues [24]. They showed that the relationship between
CFU and TTP changes over time in early response to treatment (14
days). These observations imply that MGIT detects an extra sub-
population of Mycobacterium tuberculosis and that this sub-
population decreases in number during drug exposure and treat-
ment. A similar analysis to Bowness and colleagues was not feasible
however with the data in our study due to the limited number of
samples per time point (or groups of time-points). We therefore
cannot conclude that CFU and TTP are detecting different sub-
populations of Mycobacterium tuberculosis in our mouse model.
Compared to the bi-phasic decline of CFU and TTP over time
(with the exception of HRZE), description of MBL was mono-phasic
for all four treatments with gradients on the logarithmic scale close
to zero, but MBL counts remained positive during treatment in all
four treatment arms, suggesting the presence of a mycobacterial
subpopulationwhich decreases slowly under treatment, but cannot
be detected by TTP and CFU counting. However, elimination rate
constants derived from MBL data cannot arms tested. All four
treatment arms have MBL elimination rate constants of similar
magnitude, whose differences cannot be considered statistically
signiﬁcant. In contrast to the mono-phasic elimination in the pre-
sent study, a bi-phasic decline with the MBL was observed by
Honeyborne et al. [12]. However, the study reported an EBA
measured over 14 days with the ﬁrst 3 days showing a steepergradient compared to EBA 3e14 days. The difference in observa-
tions between the Honeyborne study and the present study may be
a result of the richer initial time course studied by Honeyborne
et al. compared to sampling 1 week after start treatment in our
study. Thereby potentially failing to capture a bi-phasic decline of
the ﬁrst 3 days, which is a limitation of the current study.
At week 12, MBL numbers were higher compared to CFU and
TTP (with the exception of ZES) and at week 24 CFU counts were
negative for HRZ, HRZE and HRZS but the MBL numbers were still
positive. Because rRNA is downregulated in bacteria entering
dormancy [25], we could speculate this could infer that the MBL
assay maybe even underestimates the mycobacterial load during
the continuation phase of treatment. This could for instance explain
the failure of the MBL assay to differentiate between the efﬁcacy of
ZES and the HRZ-based regimens at the end of treatment.
In the present study, MBL also measured lower than CFU in the
early phase of treatment, indicating a less sensitive assay to detect
high numbers of actively replicating Mycobacterium tuberculosis.
This was also shown by van der Vliet et al. [26], demonstrating that
conversion of 16S rRNA to CFU must be optimized. The present
study also shows that the starting material is of inﬂuence on the
sensitivity of the assay, especially in the high range of present
bacteria. Therefore, the MBL assay must be further optimized when
Mycobacterium tuberculosis-infected tissue is the starting material.
Also notable, is the disparity between CFU and MBL counts after
12 weeks with rifampicin and isoniazid containing regimens (HRZ,
HRZE and HRZS), compared with the observation of CFU and MBL
after 12 weeks of the ZES treatment where minimal difference is
found between the two. This observation is in keeping with a
pattern where during the early phase of treatment the metaboli-
cally activeMycobacterium tuberculosis are eliminated by isoniazid,
while rifampicin is one of the drugs responsible for the elimination
during the sterilizing phase [27]. The positive MBL counts at later
time points which are not counted by the CFU and TTP assay
possibly represent a subpopulation of Mycobacterium tuberculosis,
which are in a dormant state. To add on to this, Malherbe et al.
recently showed that mRNA can still be found in a bronchoalveolar
lavage samples at the end of treatment in cured patients, also
indicating that there is a subpopulation of mycobacteria which
cannot be detected on solid media but is still present in the lungs
[28]. This suggest an important complementary role for the hosts
immune system to maintain a disease-free state and shows that
sterilizing or host-directed therapies are needed for the develop-
ment of shortened and improved treatment regimens [28].
A study by de Steenwinkel et al., aiming for a shortened treat-
ment regimen found that increasing the rifampicin dose up to
80 mg/kg/day reduced the treatment duration by four months,
without relapse of infection [29]. To add on to this, Hu et al. recently
found that increasing the rifampicin dose eventually also eliminate
the non-culturable population in their model [11]. However, Kayi-
gire et al. showed that rifampicin signiﬁcantly reduced the CFU
counts, but also signiﬁcantly changed the proportions of non-
growing, lipid body-containing mycobacteria an viable mycobac-
teria, indicating that treatment can drive mycobacteria in a non-
culturable state [30].
Therefore, additional investigation of the use of the MBL assay
with high doses of rifampicin in combination with RPFs is war-
ranted to further characterize the non-culturable subpopulation.
In conclusion, we show strong correlations between CFU, TTP,
and the MBL assay reﬂecting the ability of each to determine the
mycobacterial load in our mouse TB model. The ﬁndings also show
that the MBL assay tells “a different story” to that of CFU counts and
TTP, by detecting a subpopulation of Mycobacterium tuberculosis
which is not detected by CFU or TTP assays.
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